Artwork

Content provided by Syneos Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Syneos Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Psychedelics 3.0: Challenges and Opportunities in an Evolving Field

1:02:37
 
Share
 

Manage episode 447672609 series 2286377
Content provided by Syneos Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Syneos Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to meet those needs. In clinical trials, a wide array of these compounds are showing efficacy across a variety of indications.

Syneos Health experts Andy Moniz, Dr. Leslie Moldauer, Zelma Gandy Don Sing and Lindsay Crampton—along with Dr. Aaron Koenig, CMO of Delix Therapeutics—convened in a roundtable discussion to provide their own unique perspectives about the current and future state of psychedelic drug development and how to actively navigate the rapidly evolving field of clinical trials for these revolutionary treatments.

Listen in to hear how psychedelics have progressed from their origins as a spiritual aid, their acceptance as a treatment for neuropsychiatric conditions, and the development of next-generation compounds.

For more from our neuroscience experts, check out these insights:

Syneos Health Podcast | Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?

Artificial Intelligence and Alzheimer’s: Transforming Patient Screening with Predictive Models

WEBINAR | Psychedelics 3.0: Challenges and Opportunities

Syneos Health Podcast | World Mental Health Day: The State of Mental Health Clinical Development

BLOG | The Reimbursement Case for Psychedelic Therapies Must Incorporate the Patient’s Voice


The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].

  continue reading

172 episodes

Artwork
iconShare
 
Manage episode 447672609 series 2286377
Content provided by Syneos Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Syneos Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to meet those needs. In clinical trials, a wide array of these compounds are showing efficacy across a variety of indications.

Syneos Health experts Andy Moniz, Dr. Leslie Moldauer, Zelma Gandy Don Sing and Lindsay Crampton—along with Dr. Aaron Koenig, CMO of Delix Therapeutics—convened in a roundtable discussion to provide their own unique perspectives about the current and future state of psychedelic drug development and how to actively navigate the rapidly evolving field of clinical trials for these revolutionary treatments.

Listen in to hear how psychedelics have progressed from their origins as a spiritual aid, their acceptance as a treatment for neuropsychiatric conditions, and the development of next-generation compounds.

For more from our neuroscience experts, check out these insights:

Syneos Health Podcast | Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?

Artificial Intelligence and Alzheimer’s: Transforming Patient Screening with Predictive Models

WEBINAR | Psychedelics 3.0: Challenges and Opportunities

Syneos Health Podcast | World Mental Health Day: The State of Mental Health Clinical Development

BLOG | The Reimbursement Case for Psychedelic Therapies Must Incorporate the Patient’s Voice


The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].

  continue reading

172 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play